Gilead Sciences and partner Arcellx reported pivotal‑stage results at ASH showing deep, durable responses for their anti‑BCMA CAR‑T in multiple myeloma. Among 117 evaluable patients the companies disclosed a 96% overall tumor response rate and 74% complete remission rate, with no new safety signals in the latest analysis. The dataset positions the candidate as a potential commercial lifeline for Gilead amid softening sales in its earlier CAR‑T portfolio. The readout was presented as a pivotal analysis meant to support regulatory filings; the therapy’s safety and durability metrics will be crucial to payer negotiations and competitive positioning against existing myeloma CAR‑Ts. Company statements emphasized the trial’s size and remission depth as evidence of differentiated efficacy.